Micromet, Inc. - Product Pipeline Review - Q4 2010

Micromet, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Micromet, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Micromet, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Micromet, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Micromet, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Micromet, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Micromet, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Micromet, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Micromet, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Micromet, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Micromet, Inc. and identify potential opportunities in those areas. SHOW LESS READ MORE >

List of Tables
List of Figures
Micromet, Inc. Snapshot
Micromet, Inc. Overview
Key Information
Key Facts
Micromet, Inc. – Research and Development Overview
Key Therapeutic Areas
Micromet, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Micromet, Inc. – Pipeline Products Glance
Micromet, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Micromet, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Micromet, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Micromet, Inc. – Drug Profiles
Canvaxin
Product Description
Mechanism of Action
R&D Progress
Adecatumumab
Product Description
Mechanism of Action
R&D Progress
Adecatumumab + FOLFOX
Product Description
Mechanism of Action
R&D Progress
Blinatumomab
Product Description
Mechanism of Action
R&D Progress
Adecatumumab
Product Description
Mechanism of Action
R&D Progress
Blinatumomab
Product Description
Mechanism of Action
R&D Progress
MT110
Product Description
Mechanism of Action
R&D Progress
BiTE antibody
Product Description
Mechanism of Action
R&D Progress
BiTE-Based Cetuximab
Product Description
Mechanism of Action
R&D Progress
HUI77
Product Description
Mechanism of Action
R&D Progress
MT111
Product Description
Mechanism of Action
R&D Progress
MT204
Product Description
Mechanism of Action
R&D Progress
BiTE N.N.
Product Description
Mechanism of Action
R&D Progress
CD33 BiTE Antibody
Product Description
Mechanism of Action
R&D Progress
EGFR BiTE Antibody Program
Product Description
Mechanism of Action
R&D Progress
MCSP BiTE Antibody Program
Product Description
Mechanism of Action
R&D Progress
Micromet/Sanofi BiTE Program
Product Description
Mechanism of Action
R&D Progress
Micromet, Inc. – Pipeline Analysis
Micromet, Inc. – Pipeline Products by Therapeutic Class
Micromet, Inc. Pipeline Products By Target
Micromet, Inc. – Pipeline Products by Route of Administration
Micromet, Inc. – Pipeline Products by Molecule Type
Micromet, Inc. – Recent Pipeline Updates
Micromet, Inc. - Dormant Projects
Micromet, Inc. – Company Statement
Micromet, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Dec 07, 2010: Micromet's Blinatumomab Produces High Objective Response Rate In Spectrum Of Relapsed Non-Hodgkin's Lymphoma Patients
Dec 06, 2010: Micromet Reports Phase II Study Data Of Blinatumomab In Acute Lymphoblastic Leukemia
Dec 06, 2010: Micromet Reports Phase II Study Data Of Blinatumomab In Acute Lymphoblastic Leukemia
Nov 09, 2010: Micromet To Provide Update On BiTE Antibody R&D Programs At 2010 American Society Of Hematology Annual Meeting
Nov 09, 2010: Micromet To Provide Update On BiTE Antibody R&D Programs At 2010 American Society Of Hematology Annual Meeting
Nov 08, 2010: Micromet To Advance MT112/BAY 2010112 Into IND-Enabling Preclinical Development Activities In Collaboration With Bayer Schering Pharma
Oct 11, 2010: Micromet Announces FDA Acceptance Of IND For BiTE Antibody MT111/MEDI-565
Jun 14, 2010: Micromet Announces Updated Results From Phase II Trial Of Blinatumomab In Patients With Acute Lymphoblastic Leukemia
Jun 14, 2010: Micromet's Blinatumomab Induces Durable Remissions In Patients With Relapsed Non-Hodgkin's Lymphoma
Jun 07, 2010: Micromet Presents Interim Update On Phase I Study Of MT110 In Patients With Advanced Solid Tumors
Financial Deals Landscape
Micromet, Inc., Deals Volume Summary, 2004 to YTD 2010
Micromet, Inc., Deals Summary By Region, 2004 to YTD 2010
Micromet, Inc., Deals Summary, 2004 to YTD 2010
Micromet, Inc. Detailed Deal Summary
Private Equity
Micromet Announces Financing Of $75 Million From Kingsbridge Capital Advisors
Equity Offering
Micromet Completes Public Offering Of $80 Million
Micromet Completes Private Placement Of $25.4 Million
Micromet Completes Private Placement Of $8 Million
Bayer Schering Enters Into Co-Development Agreement With Micromet
Micromet Enters Into Co-Development Agreement With Lonza Group
Micromet Terminates Co-Development Agreement With MedImmune
Micromet Enters Into An Agreement With Nycomed International Management
Micromet Amends Its Agreement With Serono
Licensing Agreements
Micromet Enters Into Licensing Agreement With Sanofi-Aventis
Micromet Enters Into License Agreement Agreement With TRACON Pharmaceuticals
Micromet Enters Into An Agreement With Morphotek
Micromet Enters Into Licensing Agreement With Serono
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer